Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
Sunyu Kang, Kevin Gergich, Gregory M. Lubiniecki et al. · Annals of Oncology · 2017
The landscape of cancer treatment has undergone a vast change over the past four decades [1,2]. Discovery of the heterogeneous molecular features of tumors and the associated microenvironment has led to the development of novel classes of targeted therapeutics [3–5], the two main types of which are small-molecule inhibitors and monoclonal antibodies (mAbs) [1–3]. These targeted drugs have furthered the development of personalized therapeutic regimens in oncology.
Cited by 110 works. doi:10.1093/annonc/mdx076 Open-access PDF
Authors
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Hallmarks of Cancer: The Next Generation
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- The blockade of immune checkpoints in cancer immunotherapy
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Enhancement of Antitumor Immunity by CTLA-4 Blockade